NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
Clinical Trials
6 trialsNCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04958785 2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2 Terminated
NCT03725761 2025-05-13
Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT05113966 2025-01-29
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Phase 2 Terminated